NLY01, a brain-penetrant GLP-1 agonist designed to reduce neuroinflammation, showed no benefit for motor or non-motor Parkinson's symptoms in a 255-patient randomized trial published in Lancet Neurology.
p=0.77 — No benefitNLY01, a brain-penetrant GLP-1 agonist designed for Parkinson's disease, performed no better than placebo on the primary motor function endpoint in this 255-patient Lancet Neurology trial
What the researchers found
NLY01 — a brain-penetrant, pegylated, longer-lasting version of the GLP-1 agonist exenatide — showed NO benefit for Parkinson's disease in this rigorous 36-week trial. Neither the 2.5 mg nor 5.0 mg dose improved motor or non-motor symptoms compared to placebo on the MDS-UPDRS scale (p=0.77 and p=0.79, respectively).
The drug was designed to reduce brain inflammation by suppressing microglial activation, a mechanism distinct from its metabolic effects. Despite strong preclinical rationale and adequate dosing, NLY01 simply did not work for Parkinson's disease symptoms. An exploratory subgroup analysis hinted at possible motor benefit in younger patients, but this requires replication before drawing conclusions. Side effects were predominantly gastrointestinal: nausea affected 39-58% of treated patients versus 19% on placebo.
Why it matters
There has been enormous excitement about GLP-1 agonists potentially treating neurodegenerative diseases like Parkinson's and Alzheimer's. This Lancet Neurology trial delivers a sobering reality check: a purpose-built, brain-penetrant GLP-1 agonist failed to improve Parkinson's symptoms in a well-designed trial. This doesn't rule out all GLP-1 approaches for neurodegeneration, but it significantly tempers expectations and highlights how difficult it is to translate promising preclinical neuroscience into clinical benefit.
The numbers in context
n=255 randomized (85 per group) · 36-week duration · 58 sites across USA · 2.5 mg vs 5.0 mg vs placebo · Primary endpoint: p=0.77 and p=0.79 (no benefit) · Nausea: 39-58% active vs 19% placebo · No deaths · 447 screened
How the study worked
This was a 36-week, randomized, double-blind, placebo-controlled trial conducted at 58 movement disorder clinics across the United States. 255 participants with early, untreated Parkinson's disease were randomized 1:1:1 to NLY01 2.5 mg, NLY01 5.0 mg, or placebo. The primary endpoint was change in the MDS-UPDRS parts II and III (measuring motor and daily living function). All participants, investigators, and staff were blinded. Safety was monitored comprehensively including adverse events, ECGs, labs, and scales for suicidality, sleepiness, impulsivity, and depression.
Who was studied
255 adults with early, untreated Parkinson's disease across 58 US centers
What this study cannot tell us
The 36-week duration may have been insufficient to detect neuroprotective effects that emerge more slowly. The study enrolled early, untreated patients who may deteriorate slowly, making it harder to show treatment differences. The subgroup finding in younger patients is hypothesis-generating only and could be a chance finding. Parkinson's disease is heterogeneous, and microglia-mediated inflammation may only drive pathology in certain patient subgroups.
How to read the evidence
This is a large, multi-center, randomized, double-blind, placebo-controlled trial published in Lancet Neurology — one of the highest-quality study designs possible. The clear negative result is itself strong evidence that NLY01 does not benefit early Parkinson's disease symptoms at the doses and duration tested.
When this study was published
Published in 2024 with data from 2020-2023, this is the most recent and definitive trial of a GLP-1 agonist specifically designed for Parkinson's disease. Its negative result is reshaping expectations about GLP-1 neuroprotection.
The bigger picture
The idea that GLP-1 agonists could treat Parkinson's and other neurodegenerative diseases has generated tremendous excitement, driven by epidemiological associations and promising animal studies. This trial is a critical piece of reality: a purpose-designed, brain-penetrant GLP-1 agonist failed its primary endpoint. It doesn't definitively close the door on GLP-1 approaches to neurodegeneration — different drugs, longer trials, or specific patient subgroups might still show benefit — but it demands more rigorous skepticism about the neurology hype surrounding this drug class.
Questions still open
- Could a longer trial (beyond 36 weeks) reveal neuroprotective effects that weren't apparent in this timeframe?
- Does the subgroup signal in younger patients represent a real biological effect or a statistical artifact?
- Do other GLP-1 agonists like exenatide or liraglutide have different neuroprotective properties that NLY01 lacks?
Common questions
Can GLP-1 drugs like Ozempic help with Parkinson's disease?
What were the side effects of NLY01 in this trial?
Read the original research
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
The Lancet. Neurology, 23(1), 37-45
Citation
McGarry, Andrew; Rosanbalm, Shane; Leinonen, Mika; Olanow, C Warren; To, Dennis; Bell, Adam; Lee, Daniel; Chang, Jamie; Dubow, Jordan; Dhall, Rohit; Burdick, Daniel; Parashos, Sotirios; Feuerstein, Jeanne; Quinn, Joseph; Pahwa, Rajesh; Afshari, Mitra; Ramirez-Zamora, Aldolfo; Chou, Kelvin; Tarakad, Arjun; Luca, Corneliu; Klos, Kevin; Bordelon, Yvette; St Hiliare, Marie-Helene; Shprecher, David; Lee, Seulki; Dawson, Ted M; Roschke, Viktor; Kieburtz, Karl. (2024). Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.. The Lancet. Neurology, 23(1), 37-45. https://doi.org/10.1016/S1474-4422(23)00378-2